Sagimet Biosciences (SGMT) said Tuesday the US Food and Drug Administration's Division of Dermatology and Dentistry has cleared its investigational new drug application for TVB-3567.
The company said the clearance allows it to enter clinical development for the treatment of acne, with a first-in-human phase 1 trial planned in 2025.
TVB-3567 is its second fatty acid synthase inhibitor, it said.
Price: 3.37, Change: -0.17, Percent Change: -4.80
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.